Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in relapsed or refractory CD123-positive or BPDCN-like acute myeloid leukemia
2020-001543-94Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Nov 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of avacincaptad pegol in acute myeloid leukemia (AML) (2 cohorts), sponsored by GIMEMA. Primary endpoint: Primary activity endpoint. Started Nov 2020; status: terminated.
02
Drugs
avacincaptad pegol
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-001543-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001543-94.